investment

N-able: how the company's business works, is it worth investing in stocks

<img class=”aligncenter” src=”https://daytradergt.com/wp-content/uploads/2021/10/03ef1ce3fe38f6a82f5fd281a5216c89.png” alt=”N-able: how the company's business works, is it worth investing in stocks” /> Today we have a very speculative idea: take shares of cloud business N-able (NYSE: NABL), in order to make money on the rebound of these shares. Growth potential and validity: 19,5% for 14 months; 11% per annum for 15 years. Why stocks can go up: they are cheaper, than they could. How do we act: we take shares now by 12,54 $. When creating the material, sources were used, inaccessible to users from the Russian Federation. We hope, Do you know, what to do. Without guarantees Our reflections are based on the analysis of the company's business and the personal experience of our investors, but remember: not a fact, that the investment idea will work like this, as we expect. Everything, what we write, are forecasts and hypotheses, not a call to action. To rely on our reflections or not – it's up to you. If you want to be the first to know, did the investment work?, subscribe: as soon as it becomes known, we will inform. And what is there with the forecasts of the author of the Study, like this and this, talk about, that the accuracy of target price predictions is low. And that's ok: there are always too many surprises on the stock exchange and accurate forecasts are rarely realized. If the situation were reversed, then funds based on computer algorithms would show results better than people, but alas, they work worse. So we're not trying to build complex models.. The profitability forecast in the article is the author's expectations. We specify this forecast for the landmark: as with the investment idea as a whole, readers decide for themselves, it is worth trusting the author and focusing on the forecast or not. We love, appreciate,Инвестредакция На чем компания зарабатывает NABL на бирже совсем недавно — с 20 июля. …

N-able: how the company's business works, is it worth investing in stocks Read more

Apple reduces the production of new iPhones due to a shortage of chips

According to Bloomberg, in 2021 year Apple will cut production of new iPhones 13 on 11%, with 90 to 80 million devices. And all because of the lack of chips: Broadcom and Texas Instruments suppliers do not have time to supply the necessary components. Apple is one of the largest customers of chips and can often work with suppliers on more favorable terms.

Walgreens reports for the quarter and enters a new market

<img class=”aligncenter” src=”https://daytradergt.com/wp-content/uploads/2021/10/336898445233a268f78b647b30d0c34b.jpg” alt=”Walgreens reports for the quarter and enters a new market” /> Pharmacy chain Walgreens Boots Alliance (WBA) published the financial report for the fourth quarter and fiscal year 2021. Quarterly results: revenue increased by 13%, up to $34.3 billion; operating profit increased by 50%, up to 0.9 billion; net profit increased by 68%, up to 0.6 billion.

Bundle of investment news: Macy’s, how IT specialists live in the USA and who to give money to

<img class=”aligncenter” src=”https://daytradergt.com/wp-content/uploads/2021/10/7347ccba5a5305c8c9d6906d20f52147.jpg” alt=”Bundle of investment news: Macy&rsquo;s, how&nbsp;IT specialists live in the USA and to whom to give money” /> Macy's can create a new company cooler than itself. Programmers in the U.S. are ruining employers — though, nothing new. PwC gives an analysis of Americans' spending - looking for winners. We understand, how to make money on floods in the usa.

Is it worth investing in semiconductors: Semtech review

Semtech (NASDAQ: SMTC) - American semiconductor manufacturer. The company's business looks strong, and his conjuncture is positive.. But the current value of the company greatly spoils the overall picture.. What the company earns Semtech is engaged in the design and production of semiconductor components.

Merck has developed a cure for COVID 19 Molnupiravir Molnupiravir

Pharmaceutical company Merck reported, that has developed an effective cure for COVID-19 (Molnupiravir Molnupiravir). Shares of Merck and most airlines soared, while vaccine developer Moderna's papers fell by 11,4%. Merck and Ridgeback's research oral antiviral drug Molnupiravir reduced the risk of hospitalization or death by about 50 percent compared to placebo for patients with mild to moderate COVID-19 in a positive interim analysis of a phase study 3

Investidea: Hyster-Yale Materials Handling, because there is something to hold onto

Today we have a moderately speculative idea with a conservative touch: take shares of forklift manufacturer Hyster-Yale Materials Handling (NYSE: HY), to capitalize on the growth in demand for the company's products. Growth potential and validity: 14% behind 14 Months; 50% for 5 years; 109% for 10 years. All excluding dividends.

Magnit Review: grocery retailer, who fights for leadership

"Magnet" (MCX, LSE: MGNT) — the largest grocery retailer in Russia by the number of stores and the second largest grocery retailer in terms of revenue. The company is one of the largest private employers in the country with over 300,000 employees.. About Magnit's Business is present in all federal districts, except Far Eastern.

Tariffs are growing and bring profit: we analyze the report of NCSP

NMTP (MCX: NMTP) — the largest port operator in Russia. The main shareholder of the company is the state company Transneft, which owns 50,1% Shares. Over the past two months, NCSP's share price on the Moscow Exchange has increased by more than 20%, but then followed the correction to 10%.

Scroll to Top